Topical tacrolimus does not increases long-term cancer risk in children with atopic dermatitis (AD), according to study findings published in the Journal of the American Academy of Dermatology. The APPLES™ (A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis (AD); NCT00475605) study evaluated whether topical treatment with tacrolimus 0.03% or 0.1% ointment increased incidence of lymphoma and other cancers in a pediatric AD population. Children with AD were included if their first

 

 

Image by Mihai Paraschiv from Pixabay

Read more…